Algeta to Participate in Upcoming Investor Conferences

2013-02-20 07:02:47 -

Oslo, Norway, 20 February 2013 - Algeta ASA (OSE: ALGETA), a company focused on

the development of novel targeted cancer therapeutics, announces that members of

its senior management team will participate in the following upcoming investor

conferences:



 Citi Global Healthcare Conference 2013



     Date: 25-27 February 2013



     Participants:



         Jeff Albers (President, Algeta US)



         Mike Booth (IR)



     Panel date & time: Tuesday 25 February, 2013, 10:20am EST



     Venue: New York, NY, USA





 Credit Suisse Global Healthcare One-on-One Conference



     Date: 5-6 March 2013



     Participants:



         Andrew Kay (President & CEO)



         Oystein Soug (CFO)



         Mike Booth (IR)



     Venue: London, UK





 Carnegie Nordic Healthcare Seminar



     Date: 12 March 2013



     Participants:



         Thomas Ramdahl (EVP & CTO)



         Renate Birkeli (IR)



     Presentation date & time: Tuesday 12 March, 2013, 10:05am CET



     Venue: Stockholm, Sweden







Presentations, where applicable, will be available to download at www.algeta.com

following these events.



                                      ###



For further information, please contact:



 Mike Booth / Renate Birkeli            +47 23 00 67 32



 Communications & Corporate Affairs     ir@algeta.com







 Media enquiries:



 Mark Swallow                           +44 207 638 9571



 Citigate Dewe Rogerson                 mark.swallow@citigatedr.co.uk







 Knut Ekern                             +47 22 04 82 00



 Gambit Hill & Knowlton                 knut.ekern@hkstrategies.com







 Kari Watson                            +1 781 235 3060



 MacDougall Biomedical Communications   kwatson@macbiocom.com







 US investor enquiries:



 Tricia Swanson                         +1 646 378 2953



 The Trout Group                        tswanson@troutgroup.com







About Algeta



Algeta is a company focused on developing novel targeted therapies for patients

with cancer based on its alpha-pharmaceutical platform. The Company is

headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in

Cambridge, MA performing commercial marketing operations in the US. Algeta is

listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please

visit www.algeta.com.





This information is subject of the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.



Press release: 

 hugin.info/134655/R/1679229/548305.pdf







This announcement is distributed by Thomson Reuters on behalf of 

Thomson Reuters clients. The owner of this announcement warrants that: 

(i) the releases contained herein are protected by copyright and 

    other applicable laws; and 

(ii) they are solely responsible for the content, accuracy and 

     originality of the information contained therein. 

    

Source: Algeta ASA via Thomson Reuters ONE

[HUG#1679229]